WO2005070455A1 - Mucosal vaccine adjuvants containing bacterial flegellins as an active component - Google Patents
Mucosal vaccine adjuvants containing bacterial flegellins as an active component Download PDFInfo
- Publication number
- WO2005070455A1 WO2005070455A1 PCT/KR2005/000103 KR2005000103W WO2005070455A1 WO 2005070455 A1 WO2005070455 A1 WO 2005070455A1 KR 2005000103 W KR2005000103 W KR 2005000103W WO 2005070455 A1 WO2005070455 A1 WO 2005070455A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- acid sequence
- seq
- set out
- flagellin
- Prior art date
Links
- 239000012646 vaccine adjuvant Substances 0.000 title claims abstract description 24
- 229940124931 vaccine adjuvant Drugs 0.000 title claims abstract description 24
- 230000001580 bacterial effect Effects 0.000 title claims description 10
- 108010040721 Flagellin Proteins 0.000 claims abstract description 55
- 241000607265 Vibrio vulnificus Species 0.000 claims abstract description 18
- 241000186779 Listeria monocytogenes Species 0.000 claims abstract description 5
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims abstract description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 30
- 229960000814 tetanus toxoid Drugs 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 229960005486 vaccine Drugs 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 7
- 101150038062 fliC gene Proteins 0.000 claims description 4
- 230000002163 immunogen Effects 0.000 claims description 4
- 229940115931 listeria monocytogenes Drugs 0.000 claims description 4
- 101100477592 Bacillus subtilis (strain 168) sinR gene Proteins 0.000 claims description 3
- 101100281119 Brachyspira hyodysenteriae flaA1 gene Proteins 0.000 claims description 3
- 101100066776 Caulobacter vibrioides (strain ATCC 19089 / CB15) flgF gene Proteins 0.000 claims description 3
- 206010008631 Cholera Diseases 0.000 claims description 3
- 101100281209 Escherichia coli (strain K12) fliA gene Proteins 0.000 claims description 3
- 101100120228 Pseudomonas aeruginosa fliC gene Proteins 0.000 claims description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 101150071682 flaA gene Proteins 0.000 claims description 3
- 101150060393 flaC gene Proteins 0.000 claims description 3
- 101150003488 flaD gene Proteins 0.000 claims description 3
- 101150088117 flaE gene Proteins 0.000 claims description 3
- 101150023958 flaF gene Proteins 0.000 claims description 3
- 101150054723 fliI gene Proteins 0.000 claims description 3
- 101150045736 fliK gene Proteins 0.000 claims description 3
- 208000037386 Typhoid Diseases 0.000 claims description 2
- 230000000469 anti-sperm effect Effects 0.000 claims description 2
- 230000001147 anti-toxic effect Effects 0.000 claims description 2
- 230000002238 attenuated effect Effects 0.000 claims description 2
- 229940022399 cancer vaccine Drugs 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 210000004897 n-terminal region Anatomy 0.000 claims description 2
- 201000008297 typhoid fever Diseases 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 229960004854 viral vaccine Drugs 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims 6
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 claims 1
- 229940124462 contraceptive vaccine Drugs 0.000 claims 1
- 229940023041 peptide vaccine Drugs 0.000 claims 1
- 229940126583 recombinant protein vaccine Drugs 0.000 claims 1
- 210000003495 flagella Anatomy 0.000 abstract description 12
- 241000699670 Mus sp. Species 0.000 description 19
- 102000004890 Interleukin-8 Human genes 0.000 description 16
- 108090001007 Interleukin-8 Proteins 0.000 description 16
- 229940096397 interleukin-8 Drugs 0.000 description 16
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 13
- 241000282414 Homo sapiens Species 0.000 description 12
- 108010060812 Toll-like receptor 5 Proteins 0.000 description 10
- 210000004443 dendritic cell Anatomy 0.000 description 10
- 241000607142 Salmonella Species 0.000 description 9
- 102000008234 Toll-like receptor 5 Human genes 0.000 description 9
- 230000003053 immunization Effects 0.000 description 9
- 230000028993 immune response Effects 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000186781 Listeria Species 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000016379 mucosal immune response Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 241000607598 Vibrio Species 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 231100000636 lethal dose Toxicity 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- 206010043376 Tetanus Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 230000004899 motility Effects 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 235000010585 Ammi visnaga Nutrition 0.000 description 2
- 244000153158 Ammi visnaga Species 0.000 description 2
- 101100306519 Bacillus subtilis (strain 168) sigD gene Proteins 0.000 description 2
- 102100035793 CD83 antigen Human genes 0.000 description 2
- 101100066787 Caulobacter vibrioides (strain ATCC 19089 / CB15) flgG gene Proteins 0.000 description 2
- 102000009016 Cholera Toxin Human genes 0.000 description 2
- 108010049048 Cholera Toxin Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 108010055044 Tetanus Toxin Proteins 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 101150001984 flaB gene Proteins 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- -1 hydroxy aluminium Chemical compound 0.000 description 2
- 230000017730 intein-mediated protein splicing Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 108010040473 pneumococcal surface protein A Proteins 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QENJLXATANVWMR-UHFFFAOYSA-N 2-[(3-amino-3-imino-2-methylpropanethioyl)amino]acetic acid Chemical compound NC(=N)C(C)C(=S)NCC(O)=O QENJLXATANVWMR-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000218218 Ficus <angiosperm> Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 208000006731 Salmonella Food Poisoning Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 241001185086 Vibrio vulnificus MO6-24/O Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 231100000174 enterotoxicity Toxicity 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000012755 real-time RT-PCR analysis Methods 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 230000005582 sexual transmission Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000005174 swarming motility Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000029305 taxis Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- G—PHYSICS
- G02—OPTICS
- G02F—OPTICAL DEVICES OR ARRANGEMENTS FOR THE CONTROL OF LIGHT BY MODIFICATION OF THE OPTICAL PROPERTIES OF THE MEDIA OF THE ELEMENTS INVOLVED THEREIN; NON-LINEAR OPTICS; FREQUENCY-CHANGING OF LIGHT; OPTICAL LOGIC ELEMENTS; OPTICAL ANALOGUE/DIGITAL CONVERTERS
- G02F1/00—Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics
- G02F1/01—Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour
- G02F1/13—Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour based on liquid crystals, e.g. single liquid crystal display cells
- G02F1/1306—Details
- G02F1/1309—Repairing; Testing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- G—PHYSICS
- G02—OPTICS
- G02F—OPTICAL DEVICES OR ARRANGEMENTS FOR THE CONTROL OF LIGHT BY MODIFICATION OF THE OPTICAL PROPERTIES OF THE MEDIA OF THE ELEMENTS INVOLVED THEREIN; NON-LINEAR OPTICS; FREQUENCY-CHANGING OF LIGHT; OPTICAL LOGIC ELEMENTS; OPTICAL ANALOGUE/DIGITAL CONVERTERS
- G02F2203/00—Function characteristic
- G02F2203/69—Arrangements or methods for testing or calibrating a device
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Nonlinear Science (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Optics & Photonics (AREA)
- General Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005800023214A CN1909924B (en) | 2004-01-12 | 2005-01-12 | Mucosal vaccine adjuvants containing bacterial flegellins as an active component |
US10/585,880 US7914802B2 (en) | 2004-01-12 | 2005-01-12 | Mucosal vaccine adjuvants containing bacterial flagellins as an active component |
EP05721779A EP1708749B1 (en) | 2004-01-12 | 2005-01-12 | Mucosal vaccine adjuvants containing bacterial flegellins as an active component |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040001974A KR20050073865A (en) | 2004-01-12 | 2004-01-12 | Vaccine adjuvants containing constituents of the flagellum of vibrio vulnificus as an active component |
KR10-2004-0001974 | 2004-01-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005070455A1 true WO2005070455A1 (en) | 2005-08-04 |
Family
ID=36954997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2005/000103 WO2005070455A1 (en) | 2004-01-12 | 2005-01-12 | Mucosal vaccine adjuvants containing bacterial flegellins as an active component |
Country Status (5)
Country | Link |
---|---|
US (1) | US7914802B2 (en) |
EP (1) | EP1708749B1 (en) |
KR (1) | KR20050073865A (en) |
CN (1) | CN1909924B (en) |
WO (1) | WO2005070455A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2121734A1 (en) * | 2007-02-09 | 2009-11-25 | Chonnam National University | Modified flagellin improved toll-like receptor 5 stimulating activity |
WO2010141312A3 (en) * | 2009-06-01 | 2011-01-27 | Wake Forest University Health Sciences | Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same |
WO2011095649A1 (en) * | 2010-02-02 | 2011-08-11 | Instituto Nacional De Investigación Y Tecnología Agraria Y Alimentaria (Inia) | Use of flagellins from the genus marinobacter as vaccination adjuvants |
CN103041386A (en) * | 2012-11-08 | 2013-04-17 | 中国科学院海洋研究所 | Application of vibrio anguillarum recombinant protein |
CN101622272B (en) * | 2007-02-09 | 2013-07-17 | 全南大学校产学协力团 | Modified flagellin improved toll-like receptor 5 stimulating activity |
WO2014087849A1 (en) | 2012-12-04 | 2014-06-12 | 第一三共株式会社 | Adjuvant for mucous membrane vaccine |
US20160083437A1 (en) * | 2012-11-30 | 2016-03-24 | Industry Foundation Of Chonnam National University | Composition comprising recombinant fusion protein of pathogenic antigen protein and flagellin of vibrio vulnificus for preventing, alleviating, or treating aging |
KR101749317B1 (en) | 2014-09-29 | 2017-06-22 | 전남대학교산학협력단 | Compositions for prevention, improvement and treatment of Aging Phenotypes Comprising Recombinant Fusion Protein with Vibrio vulnificus Flagellin and Pathogenic Antigen |
KR101749318B1 (en) | 2014-09-29 | 2017-06-22 | 전남대학교산학협력단 | Compositions for prevention, improvement and treatment of Aging Phenotypes Comprising Recombinant Fusion Protein with Vibrio vulnificus Flagellin and Pathogenic Antigen |
US10226529B2 (en) | 2014-06-04 | 2019-03-12 | Osaka University | Adjuvant for mucosal vaccine |
US10717767B2 (en) | 2017-07-20 | 2020-07-21 | Spogen Biotech, Inc. | Bioactive polypeptides for improvements in plant protection, growth and productivity |
US11254714B2 (en) | 2012-11-30 | 2022-02-22 | Medispan Co., Ltd. | Method for inhibiting, improving, or preventing aging using recombinant fusion protein of pathogenic antigen protein and flagellin of Vibrio vulnificus |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100330190A1 (en) * | 2007-12-17 | 2010-12-30 | Compans Richard W | Immunogenic compositions and methods of use thereof |
CA2803444A1 (en) * | 2010-06-29 | 2012-01-05 | Universite Laval | Use of leukotriene b4 in combination with a toll-like receptor ligand, a rig-l-like receptor ligand or a nod-like receptor ligand to enhance the innate immune response |
EP2730287B1 (en) * | 2011-07-05 | 2018-02-28 | Suzhou Sciscape Biomedicine Science & Technology Co. Ltd. | Use of salmonella flagellin derivative in preparation of drug for preventing and treating inflammatory bowel diseases |
GB201119999D0 (en) * | 2011-11-20 | 2012-01-04 | Glaxosmithkline Biolog Sa | Vaccine |
CN103055311B (en) * | 2012-12-28 | 2014-05-21 | 中山大学 | Infectious laryngotracheitis mucosa vaccine, as well as preparation method and application thereof |
CN103861101B (en) * | 2014-03-12 | 2016-04-27 | 中国药科大学 | A kind of Novel chimeric flagellin adjuvant of helicobacter pylori polyepitope vaccines |
KR101997319B1 (en) * | 2016-06-21 | 2019-07-08 | 전남대학교산학협력단 | Manufacturing and Applications of flagellin-Adjuvanted Vaccine which induces Conformer recognizing Antibodies |
CN106362144B (en) * | 2016-10-31 | 2021-02-09 | 武汉三利生物技术有限公司 | Respiratory syncytial virus vaccine |
CA3133718A1 (en) * | 2019-03-20 | 2020-09-24 | Advagene Biopharma Co., Ltd. | Method of modulating mucosal immunogenicity |
WO2022216734A1 (en) * | 2021-04-06 | 2022-10-13 | The Board Of Trustees Of The University Of Illinois | Multivalent cholera multiepitope fusion antigen (mefa) and methods of use |
CN113384691B (en) * | 2021-06-11 | 2022-08-16 | 湖南兀邦生物科技有限公司 | Classical swine fever virus E2 protein recombinant subunit vaccine taking salmonella flagellin as molecular adjuvant and preparation method thereof |
CN114377119B (en) * | 2022-02-18 | 2023-07-25 | 海南大学 | Application of recombinant flagellin in preparation of aquatic animal vibrio harveyi resistant medicines |
CN114712392B (en) * | 2022-05-16 | 2022-11-25 | 西部医美生物科技成都有限公司双流医疗分公司 | Immune cell preparation from autologous blood separation and application thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1379552B2 (en) | 2001-04-20 | 2014-11-19 | The Institute for Systems Biology | Toll-like receptor 5 ligands and methods of use |
US20060257415A1 (en) * | 2002-09-03 | 2006-11-16 | Fondation Eurov Acc | Adjuvants |
-
2004
- 2004-01-12 KR KR1020040001974A patent/KR20050073865A/en not_active Application Discontinuation
-
2005
- 2005-01-12 WO PCT/KR2005/000103 patent/WO2005070455A1/en active Application Filing
- 2005-01-12 CN CN2005800023214A patent/CN1909924B/en active Active
- 2005-01-12 US US10/585,880 patent/US7914802B2/en active Active
- 2005-01-12 EP EP05721779A patent/EP1708749B1/en active Active
Non-Patent Citations (4)
Title |
---|
CUADROS C. ET AL: "Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses.", IN INFECT.IMMUNOL., vol. 72, no. 5, May 2004 (2004-05-01), pages 2810 - 2816, XP002392967 * |
KODARRIA C. ET AL: "Salmonella flagellin is not a dominant protective antigen in oral immunization with attenuated live vaccine strains.", IN INFECT IMMUNOL., vol. 72, no. 4, April 2004 (2004-04-01), pages 2449 - 2451, XP003009268 * |
SBROGIO-ALMEIDA M.E. ET AL: "Host and bacterial factors affecting induction of immune responses to flagellin expressed by attenuated Salmonela vaccines strains.", IN INFECT.IMMUNE., vol. 72, no. 5, May 2004 (2004-05-01), pages 2546 - 2555, XP003009267 * |
See also references of EP1708749A4 * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2121734A1 (en) * | 2007-02-09 | 2009-11-25 | Chonnam National University | Modified flagellin improved toll-like receptor 5 stimulating activity |
EP2121734A4 (en) * | 2007-02-09 | 2010-04-14 | Nat Univ Chonnam | Modified flagellin improved toll-like receptor 5 stimulating activity |
US8236327B2 (en) | 2007-02-09 | 2012-08-07 | Industry Foundation Of Chonnam National University | Modified flagellin improved toll-like receptor 5 stimulating activity |
US8337864B2 (en) | 2007-02-09 | 2012-12-25 | Industry Foundation Of Chonnam National University | Modified flagellin improved toll-like receptor 5 stimulating activity |
US8337865B2 (en) | 2007-02-09 | 2012-12-25 | Industry Foundation Of Chonnam National University | Modified flagellin improved toll-like receptor 5 stimulating activity |
CN101622272B (en) * | 2007-02-09 | 2013-07-17 | 全南大学校产学协力团 | Modified flagellin improved toll-like receptor 5 stimulating activity |
WO2010141312A3 (en) * | 2009-06-01 | 2011-01-27 | Wake Forest University Health Sciences | Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same |
US20120135037A1 (en) * | 2009-06-01 | 2012-05-31 | Mizel Steven B | Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same |
WO2011095649A1 (en) * | 2010-02-02 | 2011-08-11 | Instituto Nacional De Investigación Y Tecnología Agraria Y Alimentaria (Inia) | Use of flagellins from the genus marinobacter as vaccination adjuvants |
US9061002B2 (en) | 2010-02-02 | 2015-06-23 | Instituto Nacional De Investigación Tecnología Agraria Y Alimentaria (Inia) | Use of flagellins from the genus Marinobacter as vaccination adjuvants |
CN103041386B (en) * | 2012-11-08 | 2013-11-13 | 中国科学院海洋研究所 | Application of vibrio anguillarum recombinant protein |
CN103041386A (en) * | 2012-11-08 | 2013-04-17 | 中国科学院海洋研究所 | Application of vibrio anguillarum recombinant protein |
US20160083437A1 (en) * | 2012-11-30 | 2016-03-24 | Industry Foundation Of Chonnam National University | Composition comprising recombinant fusion protein of pathogenic antigen protein and flagellin of vibrio vulnificus for preventing, alleviating, or treating aging |
US10407471B2 (en) | 2012-11-30 | 2019-09-10 | Industry Foundation Of Chonnam National University | Composition comprising recombinant fusion protein of pathogenic antigen protein and flagellin of vibrio vulnificus for preventing, alleviating, or treating aging |
US11254714B2 (en) | 2012-11-30 | 2022-02-22 | Medispan Co., Ltd. | Method for inhibiting, improving, or preventing aging using recombinant fusion protein of pathogenic antigen protein and flagellin of Vibrio vulnificus |
WO2014087849A1 (en) | 2012-12-04 | 2014-06-12 | 第一三共株式会社 | Adjuvant for mucous membrane vaccine |
US9662386B2 (en) | 2012-12-04 | 2017-05-30 | Osaka University | Adjuvant for mucosal vaccine |
US10226529B2 (en) | 2014-06-04 | 2019-03-12 | Osaka University | Adjuvant for mucosal vaccine |
KR101749317B1 (en) | 2014-09-29 | 2017-06-22 | 전남대학교산학협력단 | Compositions for prevention, improvement and treatment of Aging Phenotypes Comprising Recombinant Fusion Protein with Vibrio vulnificus Flagellin and Pathogenic Antigen |
KR101749318B1 (en) | 2014-09-29 | 2017-06-22 | 전남대학교산학협력단 | Compositions for prevention, improvement and treatment of Aging Phenotypes Comprising Recombinant Fusion Protein with Vibrio vulnificus Flagellin and Pathogenic Antigen |
US10717767B2 (en) | 2017-07-20 | 2020-07-21 | Spogen Biotech, Inc. | Bioactive polypeptides for improvements in plant protection, growth and productivity |
US11046735B2 (en) | 2017-07-20 | 2021-06-29 | Spogen Biotech Inc. | Bioactive polypeptides for improvements in plant protection, growth and productivity |
Also Published As
Publication number | Publication date |
---|---|
US20080069844A1 (en) | 2008-03-20 |
CN1909924B (en) | 2011-04-13 |
EP1708749B1 (en) | 2012-06-27 |
CN1909924A (en) | 2007-02-07 |
EP1708749A1 (en) | 2006-10-11 |
EP1708749A4 (en) | 2009-08-05 |
US7914802B2 (en) | 2011-03-29 |
KR20050073865A (en) | 2005-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7914802B2 (en) | Mucosal vaccine adjuvants containing bacterial flagellins as an active component | |
Amani et al. | Immunogenic properties of chimeric protein from espA, eae and tir genes of Escherichia coli O157: H7 | |
Audouy et al. | Development of lactococcal GEM-based pneumococcal vaccines | |
JP2008022856A (en) | Nucleic acid and protein derived from streptococcus pneumoniae | |
Wei et al. | Immunogenicity and protective efficacy of orally or intranasally administered recombinant Lactobacillus casei expressing ETEC K99 | |
Mielcarek et al. | Nasal vaccination using live bacterial vectors | |
Yang et al. | Construction and immunological evaluation of recombinant Lactobacillus plantarum expressing SO7 of Eimeria tenella fusion DC-targeting peptide | |
JP3699421B2 (en) | Protein from Actinobacillus pleuronumonia | |
Ricci et al. | Immunogenicity of the B monomer of Escherichia coli heat-labile toxin expressed on the surface of Streptococcus gordonii | |
JP2009509496A (en) | Immunological protein of Lawsonia intracellularis | |
KR100795839B1 (en) | Mucosal vaccine adjuvants containing bacterial flagellins as an active component | |
US9310381B2 (en) | Engineered type IV pilin of Clostridium difficile | |
Won et al. | Multifaceted immune responses and protective efficacy elicited by a recombinant autolyzed Salmonella expressing FliC flagellar antigen of F18+ Escherichia coli | |
US20230256072A1 (en) | Compositions and methods for vaccination against neisseria gonorrhoeae | |
JP6401148B2 (en) | Antigens and antigen combinations | |
JP2006503825A (en) | Adjuvant | |
JP2008538502A (en) | Lawsonia protein useful as a component in subunit vaccine, and its production and use | |
Hackett | Use of Salmonella for heterologous gene expression and vaccine delivery systems | |
CN114650840A (en) | Novel vaccine for haemophilus parasuis | |
JP2023503058A (en) | A novel vaccine against Haemophilus parasuis | |
WO2006005943A1 (en) | Phage screening assay | |
KR101922414B1 (en) | Enterotoxigenic Escherichia coli that surface displaying alpha toxin of Clostridium perfringens | |
Murthy et al. | Chlamydia Vaccine: Progress and Challenges | |
WO2021120019A1 (en) | Composition for immunization and preparation method therefor | |
WO2013164334A1 (en) | Escherichia coli vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200580002321.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020067009082 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 806/MUMNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005721779 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005721779 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10585880 Country of ref document: US |